



**Value-Based Insurance Design:  
Changing the Health Care Cost Discussion from  
How Much to How Well**

**A. Mark Fendrick, MD  
University of Michigan Center for  
Value-Based Insurance Design**

**[www.vbidcenter.org](http://www.vbidcenter.org)**

**amfen@umich.edu**

**@um\_vbid**

# Improving Care and Bending the Cost Curve

- **The past several decades have produced remarkable medical innovations resulting in impressive reductions in morbidity and mortality**
- **Regardless of these advances, cost growth remains the principle focus of health reform discussions**
- **Despite unequivocal evidence of clinical benefit, Americans systematically underuse high-value services across the care spectrum**
- **Attention should turn from *how much* to *how well* we spend our health care dollars**

# Role of Consumer Cost-Sharing in Medical Spending

- **For today's discussion, our focus is on costs paid by the consumer, not the employer or insurance company**

# Impact of Cost-Sharing on Health Care Utilization


- **Ideally, consumer cost-sharing levels would be set to encourage the clinically appropriate use of health care services**
- **The archaic “one-size-fits-all” approach to consumer cost-sharing fails to acknowledge the differences in clinical value among medical interventions**

# Impact of Cost-Sharing on Health Care Utilization

## *Percentage of Americans Putting Off Medical Treatment Because of Cost*

Within the last 12 months, have you or a member of your family put off any sort of medical treatment because of the cost you would have to pay?

■ % Yes



GALLUP

**A growing body of evidence concludes that increases in cost-sharing leads consumers to reduce the use of essential care, which in some cases, leads to greater overall costs**



# Inspiration

**“I can’t believe you had to spend a million dollars to show that if you make people pay more for something, they will buy less of it.”**

**Barbara Fendrick (my mother)**

# Effects of Increased Copayments for Ambulatory Visits for Medicare Advantage Beneficiaries

## Copays increased:

- from \$7.38 to \$14.38 for primary care
- from \$12.66 to \$22.05 for specialty care
- remained unchanged at \$8.33 and \$11.38 in controls

## In the year after copayment increases:

- 19.8 **fewer** annual outpatient visits per 100 enrollees
- 2.2 **additional** hospital admissions per 100 enrollees
- Effects worse in low-income individuals and beneficiaries with chronic illness

# IBM to Drop Co-Pay for Primary-Care Visits

Article

Comments (4)



Email



Printer  
Friendly

Share:



facebook



Save This



Text



By WILLIAM M. BULKELEY

In an unusual bid to cut health-care costs, International Business Machines Corp. plans to stop requiring \$20 co-payments by employees when they visit primary-care physicians.

The company said it believed the move would save costs by encouraging people to go to primary-care doctors faster, in order to get earlier diagnoses that could save on expensive visits to specialists and emergency rooms.


IBM said that the action applies to the 80% of its workers who are enrolled in plans in which the company self-insures—that is, programs in which it pays the health-care benefits, not insurers. The new policy doesn't cover IBM employees in health-maintenance organizations.

One of the nation's largest employers with 115,000 U.S. workers, IBM spends about \$1.3 billion a year on U.S. health care. Its benefit practices are closely watched in the human-resources community, and its actions are sometimes trend-setters.




# A New Approach: Clinical Nuance

## 1. Services differ in clinical benefit produced




## 2. Clinical benefits from a specific service depend on:

Who  
receives it



Who  
provides it



Where  
it's provided



# The Solution: Clinically-Nuanced Cost Sharing

Low

Cost  Sharing

to encourage



High

Cost  Sharing

to discourage



# Value-Based Insurance Design

- **Sets consumer cost-sharing level on clinical benefit – not acquisition price – of the service**
  - Reduce or eliminate financial barriers to high-value clinical services
- **Successfully implemented by hundreds of public and private payers**



# Evidence Supporting Value-Based Insurance Design: Improving Adherence Without Increasing Costs

- Improved adherence
- Lower consumer out-of-pocket costs
- No significant increase in total spending
- Reduction in health care disparities

**EXHIBIT 1**  
Descriptions Of Value-Based Insurance Design (VBID) Policies For Prescription Drugs

Policy (year)	Study authors	Drug class targeted	Pre-VBID plan design	Copay descr
CVS Caremark (2007)	Chang et al. (Note 8 in text)	Antidiabetics	3 tiers	Copay reduced for tier 1 and
Marriott (2005)	Chernew et al. (Notes 6 and 9 in text)	Antidiabetics, ACE inhibitors/ARBs, beta-blockers, statins, steroids	3 tiers	Eliminated for tier 2 reduced to \$12.50, tier 3 reduced to \$12.50
Pitney Bowes (2007)	Choudhry et al. (Notes 10 and 11 in text) Choudhry et al. (Notes 10 and 11 in text)	Statins Clopidogrel	3 tiers 3 tiers	Eliminated for tier 2 reduced to \$12.50, tier 3 reduced to \$12.50
Novartis (2005)	Gibson et al. (Note 15 in text), Kelly et al. (Note 20 in text)	Antidiabetics, antihypertensives, bronchodilators	20% coinsurance for retail scripts, 10% coinsurance for mail-order scripts	Reduced to tier 1
Florida Health Care Coalition (2006)	Gibson et al. (Note 14 in text)	Antidiabetics	10-35% coinsurance	10% coinsurance for retail scripts, 7% coinsurance for mail-order prescriptions
Blue Cross Blue Shield of North Carolina (2008)	Maciejewski et al. (Note 16 in text), Farley et al. (Note 12 in text)	Antidiabetics, antihypertensives, cholesterol-lowering medications	10-35% coinsurance 3 tiers	10% coinsurance with disease management
State of Colorado (2006)	Nair et al. (Note 17 in text)	Antidiabetics	3 tiers	Eliminated for tier 1 for program participants, reduced for tiers 2 and 3 for all beneficiaries
Blue Cross Blue	Rodin et al. (Note 18)	Antidiabetics,	3 tiers	All drugs and testing supplies reduced to tier 1



# Value-Based Insurance Design

## Broad Multi-Stakeholder Support

- **HHS**
- **CBO**
- **SEIU**
- **MedPAC**
- **Brookings Institution**
- **The Commonwealth Fund**
- **NBCH**
- **PCPCC**
- **PhRMA**
- **AHIP**
- **NBCH**
- **National Governor's Assoc.**
- **Academy of Actuaries**
- **Bipartisan Policy Center**
- **Kaiser Family Foundation**
- **NBGH**
- **National Coalition on Health Care**
- **Urban Institute**
- **RWJF**
- **IOM**
- **US Chamber of Commerce**



# Sec 2713: Selected Preventive Services be Provided without Cost-Sharing

- **Receiving an A or B rating from the United States Preventive Services Taskforce (USPSTF)**
- **Immunizations recommended by the Advisory Committee on Immunization Practices (ACIP)**
- **Preventive care and screenings supported by the Health Resources and Services Administration (HRSA)**



Over **100 million** Americans have received expanded coverage of preventive services

# Value-Based Insurance Design Role in State Health Reform

- **State Employees Benefit Plans**
- **State Exchanges**
- **CO-OPs**
- **Medicaid**



# V-BID in Medicare: Bipartisan Political Support

## The Value-Based Insurance Design for Better Care Act of 2014

113TH CONGRESS  
2D SESSION

H. R. \_\_\_\_\_

(Original Signature of Member)

To establish a demonstration program requiring the utilization of Value-Based Insurance Design to demonstrate that reducing the copayments or coinsurance charged to Medicare beneficiaries for selected high-value prescription medications and clinical services can increase their utilization and ultimately improve clinical outcomes and lower health care expenditures.

IN THE HOUSE OF REPRESENTATIVES

Mrs. BLACK (for herself and Mr. BLUMENAUER) introduced the following bill;  
which was referred to the Committee on \_\_\_\_\_

## *The Better Care, Lower Cost Act of 2014*



Sponsored by:

U.S. Sen. Ron Wyden, D-Ore.

U.S. Sen. Johnny Isakson, R-Ga.

U.S. Rep. Erik Paulsen, R-Minn.

U.S. Rep. Peter Welch, D-Vt.



# Value-Based Insurance Design: Key Initiatives

- Applying V-BID to Specialty Medications
- Incorporating V-BID in HSA-qualified HDHPs

Supporting Consumer Access to  
Specialty Medications Through  
Value-Based Insurance Design

A. Mark Fendrick, MD  
Jason Buxbaum, MHSA  
Kimberly Westrich, MA



A consumer-directed health plan (CDHP) is an insurance product that offers lower premiums in exchange for higher patient deductibles than traditional plans. People who use CDHPs are responsible for paying for most of their routine care. The goal of CDHPs is to make customers more cost-conscious about the care they use, theoretically saving money on foregone services and lowering prices for consumers. In 2010, 18 million people were enrolled in a CDHP; in the same year nearly half of all employers reported that they planned to offer a CDHP to their employees within five years.<sup>2</sup>

CDHPs have faced criticism because the higher deductibles may cause patients to use less care. Research shows that cost sharing is increased, and that patients may be deterred from receiving needed treatment (high-value care), while preserving disincentives to care without demonstrated effectiveness (low-value care), enhancing the overall health of the population.

deductibles in most CDHP plans.<sup>3</sup> V-BID is an innovative and widely implemented approach to providing health benefits that seeks to enhance patients' clinical outcomes and constrain health care cost growth. By reducing barriers to high-value, evidence-based services and providers (often through lower costs and other patient incentives) V-BID plans can achieve improved health outcomes at any level of health care expenditure. A V-BID waiver program would ensure that consumers are not deterred from receiving needed treatment (high-value care), while preserving disincentives to care without demonstrated effectiveness (low-value care), enhancing the overall health of the population.

# Using Clinical Nuance to Align Payer and Consumer Incentives

**Many “supply side” initiatives are restructuring provider incentives:**

- **Payment reform**
  - **Global budgets**
  - **Pay-for-performance**
  - **Bundled payments**
  - **Accountable care**
- **Tiered networks**
- **Health information technology**



# Using Clinical Nuance to Align Payer and Consumer Incentives

**Unfortunately, “supply-side” initiatives have historically paid little attention to consumer decision-making or the “demand-side” of care-seeking behavior:**

- **Benefit design**
- **Shared decision-making**
- **Literacy**



# Improving Care and Bending the Cost Curve

- The ultimate test of health reform will be whether it improves health and addresses rising costs
- V-BID should be part of the solution to enhance the efficiency of health care spending

Mullainathan S. When a Co-Pay Gets in the Way of Health.  
The New York Times. 2013 Aug 10.



# Discussion

[www.vbidcenter.org](http://www.vbidcenter.org)

**@um\_vbid**

**vbidcenter@umich.edu**